|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||18.88 - 18.88|
|52-week range||15.96 - 26.40|
|Beta (5Y monthly)||0.17|
|PE ratio (TTM)||67.43|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||03 Jun 2021|
|1y target est||N/A|
On top of those pluses, these three companies all have a history of offering above-average dividends, making them solid long-term value bargains. Takeda is a Japanese biopharmaceutical company that focuses on gastroenterology, oncology, neuroscience, and rare diseases. The company's stock is up more than 9% this year, currently trading at just shy of $15.
Spanish pharmaceuticals company Grifols' shares soared on Friday as the company reported the volumes of blood plasma it collected reached pre-pandemic levels in the first quarter. Grifols' collection of the blood plasma it uses to make haematology medicines, collapsed during the COVID-19 pandemic when its collection centres around the world were closed, hitting its net profit, which fell 70% in 2021. As a result Grifols lost around 50% of its market value since the COVID-19 pandemic started in 2020 when its shares were trading at record levels.
BARCELONA (Reuters) -Spanish pharmaceuticals company Grifols' full-year net profit fell 70% to 183 million euros ($204.70 million) as the COVID-19 pandemic continued to disrupt supplies of the blood plasma it uses to make medicines. Grifols said the pandemic had a negative impact of 503 million euros on core earnings, mainly because of lower collection of blood plasma, which was down 4% year on year, though there was an improvement in the fourth quarter. The Barcelona-based company expects plasma collection to continue rising in 2022, which would reduce the blood's cost and increase Grifols' profitability, it said in a statement.